Analysts at Canaccord Genuity initiated coverage on shares of Nps Pharmaceuticals Incorporated (NASDAQ: NPSP) in a research report issued to clients and investors on Monday. The firm set a “buy” rating on the stock.
Several other analysts have also recently commented on the stock. Analysts at Needham & Company reiterated a “buy” rating on shares of Nps Pharmaceuticals Incorporated in a research note to investors on Friday.
Nps Pharmaceuticals Incorporated traded down 1.81% on Monday, hitting $6.8637. Nps Pharmaceuticals Incorporated has a 52-week low of $4.35 and a 52-week high of $10.75. The company’s market cap is $591.3 million.
Nps Pharmaceuticals Incorporated last posted its quarterly earnings results on Thursday, May 3rd. The company reported ($0.12) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Analysts expect that Nps Pharmaceuticals Incorporated will post $-0.08 EPS next quarter.
NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on the development of new treatment options for patients with gastrointestinal and endocrine disorders and medical needs.